BiotechTube

Etrasimod + Placebo + Corticosteroids

Phase 2Withdrawn
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immune Checkpoint Inhibitor-Related Diarrhea and Colitis

Conditions

Immune Checkpoint Inhibitor-Related Diarrhea and Colitis

Trial Timeline

Jan 1, 2026 → Jan 1, 2029

NCT ID
NCT06521762

About Etrasimod + Placebo + Corticosteroids

Etrasimod + Placebo + Corticosteroids is a phase 2 stage product being developed by Pfizer for Immune Checkpoint Inhibitor-Related Diarrhea and Colitis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06521762. Target conditions include Immune Checkpoint Inhibitor-Related Diarrhea and Colitis.

What happened to similar drugs?

7 of 20 similar drugs in Immune Checkpoint Inhibitor-Related Diarrhea and Colitis were approved

Approved (7) Terminated (2) Active (13)
✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
✅IgPro10CSLApproved
✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved
✅Methylprednisolone + PrednisoloneBiogenApproved
✅Flebogamma 5% DIFGrifolsApproved
✅Asceniv™ADMA BiologicsApproved
✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06521762Phase 2Withdrawn

Competing Products

20 competing products in Immune Checkpoint Inhibitor-Related Diarrhea and Colitis

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
SatralizumabChugai PharmaceuticalPhase 3
47
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
RomiplostimKyowa KirinPhase 1/2
32
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
40
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
HerombopagJiangsu Hengrui MedicinePhase 3
36
Zostavax®MerckPre-clinical
18
Raltegravir + AtazanavirMerckPre-clinical
26
ZostavaxMerckPre-clinical
26
MK-8723 + Matching PlaceboMerckPhase 1
29